Skip to content
GLP-1 Scorecard
Menu

Head-to-head · WeighScore

Fitish vs HealthSource

By GLP-1 ScorecardUpdated

Fitish
Site position #349

Lower grade

HealthSource
Site position #105

Higher grade

Score comparison

HealthSource has the higher recorded score — 71.2/100 to 60.9/100.

HealthSource grades higher on WeighScore, our editorial score across cost value, dose & formulation, clinical oversight, labs & monitoring, fulfillment and contract terms. HealthSource is a telehealth weight-management platform offering compounded semaglutide and tirzepatide (injectable and oral sublingual) dispensed through a US-based FDA 503A licensed partner pharmacy.

We may earn a commission through these links, at no extra cost to you. Commercial relationships affect placement, but never the WeighScore or our editorial findings. See our disclosure.

Factor by factor

These are recorded editorial marks, not a measure of clinical outcomes. Current prices and terms may differ from those used in the marks. See the methodology.

Cost valueHealthSource +15
51
66
Dose & formulationHealthSource +8
75
83
Clinical oversightHealthSource +25
55
80
Labs & monitoringHealthSource +2
52
54
FulfillmentFitish +3
83
80
Contract termsEven
55
55
Fitish · top barHealthSource · bottom bar

The numbers

Swipe or scroll to compare both providers.

MetricFitishHealthSource
WeighScore60.9/10071.2/100
GradeCC
Site position#349#105
Semaglutide$219/mo (compounded)$199/mo (all doses, compounded)
Tirzepatide$339/mo (compounded)$299/mo (all doses, compounded)
CoverageAll 50 statesAll 50 states
Brand-name accessNot confirmedNot confirmed
Oral / sublingualYesYes
Fitish

Site position #349 · C

FDAWarning letter issued to FITISH in June 2026. See the FDA warning-letter database.

Strengths

  • LegitScript certified
  • Ships to all US states
  • Price includes consult, shipping, and medication
  • Injectable and oral tablet formats
  • Microdosing option available

What to consider

  • No physical address disclosed
  • Broader wellness/beauty brand — GLP-1 is one product line
  • Compounded only — no brand-name options
  • FDA issued FITISH a warning letter in June 2026; the letter is public in FDA's warning-letter database
HealthSource

Site position #105 · C

Strengths

  • Three GLP-1 options: compounded semaglutide injection, tirzepatide injection, and oral sublingual tirzepatide
  • 24/7 access to care team via HIPAA-compliant platform with unlimited physician messaging
  • Every program covers the cost of medication, supplies, and telehealth visits — no separate pharmacy fee
  • Subscription auto-refund if monthly reassessment is not completed
  • Available in all 50 US states including Alaska and Hawaii with 3–5 day shipping

What to consider

  • No physician names or clinical leadership disclosed on public pages
  • No LegitScript certification found
  • 503A partner pharmacy not named — less transparent than providers disclosing their 503B pharmacy
  • Labs not mentioned on any product page — baseline bloodwork protocol unknown
  • WooCommerce e-commerce storefront may feel more transactional than clinical

Featured provider

CoreAge Rx

CoreAge Rx scores 89.5/100 (B+). Advertises pricing across doses with no membership fee, but starting-price displays and FAQ payment/refund promises need to be reconciled with the selected plan and refund policy.

Commercial relationships affect this placement. The score comparison above is separate.

Pricing/verification reflect each provider's public disclosures at last grading; the WeighScore is our editorial judgment per the methodology. Prices change — confirm on each provider's site. Not medical advice; see our disclosure.

← Back to the scorecard